Development of vaccines for high-risk ductal carcinoma in situ of the breast
/in Breast Cancer, International Publications /von 2007-07-15 / Cancer Res. 2007 Jul;67(14):6531-4Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates
/in Breast Cancer, International Publications /von 2007-07-01 / Anticancer Res. 2007 Jul-Aug;27(4B):2121-9Reversing adriamycin resistance of human breast cancer cells by hyperthermia combined with Interferon alpha and Verapamil
/in Breast Cancer, Hyperthermia, International Publications /von 2007-06-01 / J. Exp. Clin. Cancer Res. 2007 Jun;26(2):201-7Counterpoint: Hyperthermia with radiation therapy for chest wall recurrences
/in Breast Cancer, Hyperthermia, International Publications /von 2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):345-8Point: Hyperthermia with radiation for chest wall recurrences
/in Breast Cancer, Hyperthermia, International Publications /von 2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):339-44Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
/in Breast Cancer, Dendritic Cells, International Publications /von 2007-02-09 / Cancer Res 2007 Feb;67(4):1842-52Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
/in Breast Cancer, Dendritic Cells, International Publications /von 2007-02-07 / Cancer Immunol Immunother 2007 Sep;56(9):1485-99Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells
/in Breast Cancer, International Publications /von 2007-01-03 / Vaccine 2007 Mar;25(14):2610-9[Induction of specific CTL by DC from axillary lymph node of patients with breast cancer]
/in Breast Cancer, International Publications /von 2007-01-01 / Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007 Jan;23(1):60-2IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de